Inherited faults (‘mutations’) in the breast cancer gene, BRCA2, can lead to cancers of the breast, ovary or other organs. BRCA2 codes for a protein containing 3,418 building blocks (called […]

Ayako Nakamura-Ishizu 1, Desmond Chin 2, Takayoshi Matsumura 2, Darren Qiancheng Tan 2, Makiko Kashio Mochizuki 1, Deng Jianwen 2, Toshio Suda 3 1Tokyo women’s medical univeristy, Tokyo, Japan. 2National University of Singapore, Singapore, Singapore. 3Kumamoto Univerisity IRCMS, Japan. Abstract Hematopoietic stem cells

Michal M Hoppe 1, Patrick Jaynes 1, Joanna D Wardyn 1, Sai Srinivas Upadhyayula 1, Tuan Zea Tan 1, Stefanus Lie 1, Diana G Z Lim 2, Brendan N K Pang 1 2, Sherlly Lim 1, Joe P S Yeong 1, Anthony Karnezis 3, Derek S Chiu 3, Samuel Leung 3, David G Huntsman 3, Anna S Sedukhina 4, Ko Sato 4, Monique

Maroni G, Bassal MA, Krishnan I, Fhu CW, Savova V, Zilionis R, Maymi VA, Pandell N, Csizmadia E, Zhang J, Storti B, Castaño J, Panella R, Li J, Gustafson CE,

The pathways that control the behaviour of cells are complex, non-linear and highly redundant. As such, identifying the right molecular target for the development of next-generation drugs is oftentimes akin

ATP-hydrolyzing enzymes like protein kinases are major drug targets for oncology. Drugs that inhibit these enzymes typically engage their ATP-binding (active) sites to inhibit catalysis. However, these active sites are

Credit: National University Cancer Institute, Singapore (NCIS) CSI Principal Investigator, Dr. Anand Jeyasekharan, wasrecently involved in a pioneering study performed by the Icahn School of Medicine at Mount Sinai in